drugset / Trial / NCT01634165

A Study of LY2963016 in Healthy Participants

NCT01634165

Phase 1 Completed 24 enrolled Eli Lilly and Company
RandomizedCrossoverDouble-blindBasic science

Summary

This study involves 2 single injections of LY2963016 and 2 single injections of Lantus. There will be at least 6 days between each injection. The study will compare LY2963016 to Lantus at two different doses. This study is approximately 10 weeks long, not including screening. Screening is required within 4 weeks of the start of the study.

Timeline

Start
2012-07
Primary completion
2012-09
Completion
2012-09

Drugs

EvaluationDrugModalityDoseRoute
Subject LY2963016 Protein / enzyme biologic 0.3 iu/kg Subcutaneous
Subject LY2963016 Protein / enzyme biologic 0.6 iu/kg Subcutaneous
Subject insulin glargine Protein / enzyme biologic 0.3 iu/kg Subcutaneous
Subject insulin glargine Protein / enzyme biologic 0.6 iu/kg Subcutaneous

Indications

No indication recorded.